Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $95M total ($50M Series A Jan 2026 + $45M extension Mar 2026) from SR One, Vida, RA Capital, Janus Henderson. Triple-action anti-IgE mechanism. Phase 1 data expected H2 2026 for PHB-050.
Poplar Therapeutics (formerly Phylaxis Bioscience) raised $95 million in less than 60 days — $50 million in Series A financing in January 2026 from SR One, Vida Ventures, RA Capital, and Janus Henderson, extended by $45 million in March 2026 — reflecting exceptional investor conviction in its PHB-050 anti-IgE program. PHB-050 uses a triple-action anti-IgE mechanism designed to exceed the performance of existing anti-IgE drugs: simultaneously blocking mast cell IgE binding, reducing circulating free IgE, and inhibiting IgE production by B cells. Phase 1 data is expected in the second half of 2026.
Aleph Alpha raised €500M+ and pivoted to sovereign AI solutions for European governments, positioning as the leading provider of GDPR-compliant, EU-hosted AI infrastructure for regulated industries.
Aleph Alpha is a German AI company building sovereign AI infrastructure for European governments and enterprises that require data sovereignty, GDPR compliance, and AI hosted within EU borders. Its Pharia AI platform provides LLM capabilities deployed on-premises or in EU data centers, serving German federal ministries, European defense agencies, and regulated industries including banking, healthcare, and legal services.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.